Aminoglutethimide and metyrapone in the management of Cushing's syndrome.
Fifteen patients with endogenous Cushing's syndrome were treated with metyrapone and/or amino-glutethimide. The duration of the therapy varied from 19 up to 365 days. In patients with Cushing's disease, metyrapone (0.5-2.5 g/day) and aminoglutethimide (0.5-1.5 g/day) seemed equally effective in reducing the cortisol excretion (54 +/- 9 vs 40 +/- 7%). The majority of these patients also showed a clinical improvement. In 1 patient with adrenal adenoma, metyrapone induced a remission. In another patient with adrenocortical cancer, and in 2 with the ectopic ACTH syndrome, the cortisol excretion was significantly reduced by the combination of metyrapone and aminoglutethimide but no obvious clinical improvement was observed. Side effects i.e. rash and pruritus attributed to aminoglutethimide was seen in 3 patients which necessitated the omission of treatment in 2. On metyrapone a moderate hypertrichosis was observed in 1 patient. In conclusion both metyrapone and aminoglutethimide were useful as adjunctive therapy in Cushing's syndrome.
D000182:ACTH Syndrome, Ectopic / Q000188:drug therapy; D000293:Adolescent; D000310:Adrenal Gland Neoplasms / Q000188:drug therapy; D000328:Adult; D000616:Aminoglutethimide / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003480:Cushing Syndrome / Q000188:drug therapy* / Q000652:urine; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000652:urine; D008297:Male; D008797:Metyrapone / Q000627:therapeutic use*; D008875:Middle Aged; D012189:Retrospective Studies
D000616:Aminoglutethimide; D006854:Hydrocortisone; D008797:Metyrapone